Abstract
Atherosclerosis is a global health issue. Atherosclerotic plaques are hardened cholesterol deposits caused primarily by a continuous fibro-inflammatory process. Treatment strategies that specifically target plaque remain a major challenge. This thesis explores the use of a novel peptide, CSG, to specifically target fibrous plaques and establishes a biologic agent, TNFa-CSG,as a potent anti-atherosclerotic drug. CSG shows specific binding to fibrous plaque in ApoE-null mice and to human plaques. Treatment of aged ApoE-null mice, bearing advanced fibrous plaque lesions with TNFa-CSG caused significant reduction of plaque. The potential of TNFa-CSG as an anti-atherosclerotic agent should be developed further.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 2 Sept 2019 |
| DOIs | |
| Publication status | Unpublished - 2019 |
Embargo information
- Embargoed from 10/09/2019 to 10/09/2022. Made publicly available on 10/09/2022.
Access to Document
- THESIS - DOCTOR OF PHILOSOPHY - AZME Nasibah - 2019
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.